High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production

National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

Research output: Contribution to journalArticle

Abstract

Tumor necrosis factor-α (TNF) may activate human immunodeficiency virus (HIV), antagonize zidovudine activity, and contribute to AIDS wasting syndrome. Pentoxifylline decreases TNF production. In cell culture, pentoxifylline decreases HIV replication and gene expression. Since an AIDS Clinical Trial Group study suggested that pentoxifylline (400 mg thrice daily) is safe in AIDS patients and decreases TNF mRNA levels in peripheral blood mononuclear cells (PBMC), a second cohort received 800 mg thrice daily for 8 weeks. During treatment, the median decrease in TNF production by PBMC cultured with 0.1 μg/mL lipopolysaccharide (LPS) was 40%. The median change in TNF mRNA was a 34% decrease. Pentoxifylline did not affect HIV levels as detected by Quantitative microculture or serum p24 antigen measurements, nor did it alter zidovudine pharmacokinetics. The most common toxicity was gastrointestinal. Pentoxifylline at dosages of less than thrice-daily 800 mg is well tolerated and may decrease TNF mRNA levels and LPS-induced TNF production.

Original languageEnglish (US)
Pages (from-to)1628-1632
Number of pages5
JournalJournal of Infectious Diseases
Volume171
Issue number6
DOIs
StatePublished - Jun 1995

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production'. Together they form a unique fingerprint.

  • Cite this

    National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group (1995). High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production. Journal of Infectious Diseases, 171(6), 1628-1632. https://doi.org/10.1093/infdis/171.6.1628